Unlock instant, AI-driven research and patent intelligence for your innovation.

Purified nontypable Haemophilus influenzae P5 protein as a vaccine for nontypable Haemophilus influenzae infection

a technology of nontypable haemophilus influenzae and p5 protein, which is applied in the direction of peptides, sense disorders, drug compositions, etc., can solve the problem that the antibodies of capsules cannot be effective at preventing nthi infections

Inactive Publication Date: 2002-06-11
AMERICAN CYANAMID CO
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

It is a further object of the present invention to provide a method of purifying P5 protein from the outer membrane of Haemophilus influenzae bacteria and which yields protein which can be used to produce active an

Problems solved by technology

Therefore, antibodies to capsule will not be effective at preventing NTHi infections.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purified nontypable Haemophilus influenzae P5 protein as a vaccine for nontypable Haemophilus influenzae infection
  • Purified nontypable Haemophilus influenzae P5 protein as a vaccine for nontypable Haemophilus influenzae infection
  • Purified nontypable Haemophilus influenzae P5 protein as a vaccine for nontypable Haemophilus influenzae infection

Examples

Experimental program
Comparison scheme
Effect test

example 1

Purification of P5

Protein extracts of P5 are obtained from both NTHi and Hib strains by differential detergent extraction of outer membranes. Following Zwittergent octylglucoside 3-14 and Zwittergent 3-14 and 0.5M NaCl extractions the P5 protein is solubilized with 1% sarcosyl in 50 mM Tris-HCl, pH8, 5 mM Na.sub.2 EDTA. The extracts are adjusted to 1% Zwittergent.TM. 3-14 in the same buffer and dialyzed against 10 fold excess of 1% Zwittergent.TM. 3-14 in 50 mM Tris-HCl, pH8, 5 mM Na.sub.2 EDTA (3.times.) over 24 hours. The dialyzed extract is then passed through an anion exchange (DEAE) column and a cation exchange (S) column connected in tandem. The columns are separated and the S column is eluted with an increasing salt gradient in the same Zwittergent containing buffer. The purified P5 protein is eluted as a single peak as analyzed by SDS-PAGE (FIG. 1).

example 2

Protease Digestion, Peptide Isolation, and Protein Sequencing

Purified NTHi P5 and Hib P5 are used directly to determine the amino acid sequence .[.(FIG. 2).]. .Iadd.(FIGS. 2A and 2B).Iaddend. (SEQ ID NO:1). Total sequence of the NTHi Protein (SEQ ID NO:1) is determined by obtaining overlapping peptides by protease digestion with several proteases including endopeptidases Lys-C. Arg-C, Glu-C, papain, trypsin, and chymotrypsin. Cyanogen bromide also is used to cleave the protein, at methionine residues to create large fragments. The peptides are isolated using a microbore High Performance Liquid Chromatograph (HPLC) and the sequences determined with a protein seqencor. Alignment of the peptides utilizes overlapping peptides and homology to the E. coli OmpA protein .[.(FIG. 2).]. .Iadd.(FIGS. 2A and 2B).Iaddend..

example 3

Whole Cell Elisa Assay

Whole formalin fixed Haemophilus Influenzae cells from several different strains are prepared from mid-log phase cells grown to OD.sub.490 =1.0 in BHI-XV media. Cells are washed twice in Phosphate Buffered Saline (PBS) (7 mM NaHPO4-7H20, 2 mM KH2PO4, 2 mM CK1, 137 mM NaCl pH7.4) then resuspended in PBS with 0.3% formalin and incubated at room temperature for 1-2 hours. Formalin is removed by washing cells in PBS and resuspending cells in PBS to a final concentration OD.sub.620 =0.2. Seventy-five microliters of cells are then added to the wells of microtiter plates and dried overnight at 37.degree. C. Plates are blocked with PBS-0.1% Tween-20 for one hour and washed in a microplate washer. One Hundred microliters of antiserum diluted in phosphate buffered saline containing 0.15 mM CaCl.sub.2, 0.5 mM MgCl.sub.2, 1% gelatin and 0.3% Tween-20 (PCM-GT) are added to the wells and plates are incubated at 37.degree. C. for two hours. After washing, bound antibodies wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to P5 outer membrane protein of the non-typable Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use in the treatment of non-typable Haemophilus influenzae infection.

Description

.Iadd.This is a reissue of U.S. Pat. No. 5,770,213 issued on Jun. 23, 1998 from application Ser. No. 08 / 210,394 filed on May 5, 1994..Iaddend.FIELD OF INVENTIONThe present invention relates to P5 outer membrane protein of the Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use in the treatment of Haemophilus influenzae infection.BACKGROUND OF INVENTIONHaemophilus influenzae strains are divided into two groups, typable and nontypable. Strains which possess a known capsule are typed by a serological reaction of the capsule with reference antisera. Currently, types a-f have been identified as typable. Strains which do not possess a capsule and fail to react with any of the reference antisera are nontypable.Nontypable Haemophilus influenzae (NTHI) infections are implicated in several disease states including otitis media, sinusitis, and chronic pulmonary obstructiv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/195C07K14/285A61K39/00C12N15/09A61K38/00A61K39/102A61P31/04C07K14/11C07K14/41C07K14/705C12Q1/68
CPCA61K38/00A61K39/00C07K14/285Y10S530/807Y10S424/831A61P11/00A61P27/16A61P31/04A61P31/16A61K39/12
Inventor ZLOTNICK, GARY W.
Owner AMERICAN CYANAMID CO